Metastatic Breast Cancer
News
FDA expands indication for ribociclib for advanced breast cancer
Approval of the CDK 4/6 inhibitor was expanded to include the treatment of pre/perimenopausal women with HR-positive, HER2-negative, in...
News
FDA approves abemaciclib for advanced breast cancer
The indication for the CDK4/6 inhibitor includes treatment in combination with fulvestrant and as a single agent.
News
HER2 status differed between primary tumor and CTCs in 18.8% of women with MBC
The probability of HER2 status discordance decreased with increasing age, but increased with primary tumors that were hormone-receptor positive,...
Conference Coverage
VIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017
Expert provides take-home messages on pertuzumab, PARP inhibitors, and CDK4/6 inhibitors.
Conference Coverage
VIDEO: NCI estimation of MBC numbers a start, but more is needed
SEER data on metastatic breast cancer includes only those diagnosed de novo and not women who were diagnosed following a metastatic recurrence of...
Conference Coverage
VIDEO: Metastatic Trial Search links MBC patients to relevant trials
CHICAGO – A breast cancer advocate discusses mixed response from physicians and barriers to trial participation faced by patients.